• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

China Drives Another Nail in the Coffins of GNC and Vitamin Shoppe

Stand-alone vitamin and supplement shops like GNC and Vitamin Shoppe shares will continue to fall in light of a Justice Department investigation.
By CARLETON ENGLISH Nov 23, 2015 | 12:00 PM EST
Stocks quotes in this article: PRGO, GNC, VSI, AMZN, NUS

Last Tuesday, after the U.S. Justice Department leveled charges against the dietary supplement industry, shares of GNC (GNC) and Vitamin Shoppe (VSI) fell 24% and 8%, respectively, even though neither was mentioned specifically in the indictment. The charges against the industry targeted the mislabeling of ingredients from China used in a supplement that was banned in 2013.

These allegations appear to be yet another nail in the coffin of an industry that already has had a bad year due to similar allegations elsewhere and challenges to their business model, and as more people buy their supplements on Amazon (AMZN). GNC shares are down 38% year to date and Vitamin Shoppe stock is down 39%.

Looking back even further, Chris Versace, columnist for Real Money and porfolio manager for Growth Seeker and Trifecta Stocks predicted the decline of GNC and Vitamin Shoppe in December 2013 as evidence emerged that users of supplements found no improvement in cognitive ability when compared to placebo groups.

At the time, Versace said, "it would be prudent for investors who have been in the shares of GNC, Vitamin Shoppe, Nu Skin (NUS) and Vitacost for several quarters to trim back positions and take some profits off the table as Wall Street looks to recalibrate its growth expectations for these companies." Since then, shares of GNC and Vitamin Shoppe are down 49% and 43%, respectively.

Tuesday's charges, however, represent the first time Chinese ingredients were mentioned in an investigation of this scale. While the indictment did not list GNC or Vitamin Shoppe, it did call out USPlabs, which produced OxyElite Pro, a supplement that was sold in GNC and Vitamin Shoppe stores until 2013. On Thursday, GNC announced that it would no longer sell products made by USPlabs.

The Justice Department indictment alleges that USPlabs "engaged in a conspiracy to import ingredients from China using false certificates of analysis and false labeling and then lied about the source and nature of those ingredients after it put them in its products." Also, "USPlabs told some of its retailers and wholesalers that it used natural plant extracts in products called Jack3d and OxyElite Pro, when in fact it was using a synthetic stimulant manufactured in a Chinese chemical factory."

The Justice Department's case raises questions as to whether GNC and Vitamin Shoppe have more mislabeled products -- possibly made in China -- sitting on their shelves undiscovered. Both companies have a history of pulling products from the shelves due to safety concerns but not pulling similar products from their shelves at the same time. For example, in the wake of the issues surrounding Jack3d and OxyElite Pro, GNC and The Vitamin Shoppe continued to sell Redline White Heat and Oxy Therm Pro, which contained DMBA, a similar stimulant to the DMAA found in USPlabs products. The DMBA-containing products were pulled from shelves late in 2014 following pressure from U.S. senators and scientists.

For its part, GNC said in a statement that it "provided its full cooperation to the authorities" and that it was "committed to maintaining the trust and confidence of our customers." Meanwhile Vitamin Shoppe offered the following: "The Vitamin Shoppe continues to support strong steps by the appropriate regulatory bodies in oversight and to ensure compliance to protect consumers."

The continuing threat of tainted Chinese imports, as well as falsely labeled vitamins, is likely to continue to weigh on GNC and Vitamin Shoppe as more details emerge. For a quick refresher as to why there is growing concern about ingredients from China, recall several incidents that made headlines. Earlier this year, Lumber Liquidators' (LL) laminate flooring made in China was found to contain formaldehyde, a known carcinogen; in 2014, Petco stopped selling pet food made in China following an FDA investigation that found contaminants in vegetable proteins imported from China; in 2007 lead paint was found in Mattel (MAT) toys made in China. With respect to Lumber Liquidators, shares of the company's stock are down 73% since March, when "60 Minutes" aired its report about the laminate flooring made in China.

A cynical person would say the business model of GNC and Vitamin Shoppe consists of making money before they get caught for putting the lives of its consumers at risk.

The threat from China was enough for Perrigo (PRGO), a manufacturer of generic healthcare products, to announce in October that it was getting out of the vitamins, minerals, and supplement (VMS) business. During the company's first-quarter earnings call, Perrigo CEO Joe Papa spoke of pricing pressure the company face from oversees.

"There is product coming in from China into the United States that at this time we do not believe is properly labeled, made in China, and it's being sold in the U.S.," Papa said. "That's something that we do think we will get resolved, but I don't want to put a specific time on it because things like that take quite a long time. But that pressure on products coming in from China has been noticed in our pricing for our VMS category in the competitive side. So that is clearly an issue."

On Thursday, Jim Cramer advised on "Mad Money" that investors in GNC may want to look to Perrigo as an antidote to GNC's falling shares.

For everyone else -- vitamin users and potential investors alike -- it may just be best to stay away from GNC and Vitamin Shoppe.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Cooper Cos. Can Rally Further After Some Sideways Consolidation

Bruce Kamich
Dec 5, 2019 2:42 PM EST

Time to review the charts and indicators.

This Dividend Stock Is Tipping the Scales for Investors

Chris Versace
Dec 5, 2019 2:08 PM EST

As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.

Avita Medical Could Double in 2020 but Not Without Risk

Bruce Kamich
Dec 5, 2019 9:53 AM EST

A 'promising' stock.

Raise Stops on NovoCure

Bruce Kamich
Dec 4, 2019 2:55 PM EST

NVCR's prices are poised to head higher in the months ahead.

UNH Passes Checkup, but Not With Flying Colors

Timothy Collins
Dec 3, 2019 1:42 PM EST

Despite fluff and puff of UNH's analysts' day, little here screams for getting in right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:06 PM EST CAROLYN BORODEN

    MRK and LVS Targets Coming Up

    View Chart » View in New Window »  LVS View C...
  • 12:01 PM EST BOB LANG

    Rolling up Apple

    just the other day we added some apple calls on th...
  • 12:24 PM EST GARY BERMAN

    Fibocall: The SPX-Cash Long-Term View

    You will hear from many analysts on TV screaming t...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login